Skip to main content
. 2020 Feb 17;2020:1508764. doi: 10.1155/2020/1508764

Table 1.

Study characteristics.

Study (author, year) Exp # Species Age (wk) Sex Obesity model Challenge Observation period
Type GT/DC Type Strain Route Dose
Single-strain bacteria models
Hsu, 2007 1 Mouse 8–12 F Gen ob/ob S. pneumoniae n/a IT 105 CFU 10 d
2 Mouse 8–12 M Gen ob/ob/lep S. pneumoniae n/a IT 105 CFU 10 d
Strandberg, 2009 3 Mouse 5–7 M Gen ob/ob S. aureus n/a IV 5 × 107 CFU 17 d
4 Mouse 5–7 M DIO HFD S. aureus n/a IV 5 × 107 CFU 17 d
Mancuso, 2014 5 Mouse 16–18 F Gen CPEF/F S. pneumoniae n/a IT 5 × 104 CFU 10 d
Svahn, 2015 6 Mouse 6 M DIO HFDP S. aureus n/a IV 3.8–4.5 × 107 CFU 17 d
7 Mouse 6 M DIO HFDS S. aureus n/a IV 3.8–4.5 × 107 CFU 17 d
8 Mouse 6 M DIO HFDS-HP S. aureus n/a IV 3.8–4.5 × 107 CFU 17 d
9 Mouse 6 M DIO HFDS-LP S. aureus n/a IV 3.8–4.5 × 107 CFU 17 d
Svahn, 2016 10 Mouse 6 M DIO HFDS S. aureus n/a IV 3–5.4 × 107 CFU 17 d
11 Mouse 6 M DIO HFDw6 S. aureus n/a IV 3–5.4 × 107 CFU 17 d
Wan, 2016 12 Mouse 3-4 M DIO HFD E. coli n/a IN 109 CFU 96 h
13 Mouse 3-4 M DIO HFD E. coli n/a IN 1010 CFU 96 h
Cecal ligation and puncture models
Tschop, 2010 14 Mouse 6–10 M Gen ob/ob Polymicrobial n/a IP n/a 240 h
15 Mouse 6–10 M DIO HFD Polymicrobial n/a IP n/a 240 h
16 Mouse 6–10 M Gen ob/ob Polymicrobial n/a IP n/a 240 h
Kaplan, 2012 17 Mouse 6 M DIO HFD Polymicrobial n/a IP n/a 30 h
Siegl, 2014 18 Mouse 19 M DIO HFD Polymicrobial n/a IP n/a 240 h
Kaplan, 2016 19 Mouse 6 M DIO HFD Polymicrobial n/a IP n/a 48 h
Lipopolysaccharide
Fagioni, 1998 20 Mouse 5 F Gen ob/ob E. coli 055:B5 n/a IP 30 μg 7 d
21 Mouse 5 F Gen ob/ob E. coli 055:B5 n/a IP 100 μg 7 d
22 Mouse 5 F Gen ob/ob E. coli 055:B5 n/a IP 300 μg 7 d
23 Mouse 5 F Gen db/db E. coli 055:B5 n/a IP 30 μg 7 d
24 Mouse 5 F Gen db/db E. coli 055:B5 n/a IP 100 μg 7 d
25 Mouse 5 F Gen db/db E. coli 055:B5 n/a IP 300 μg 7 d
Segersvard, 2003 26 Rat NR M DIO HFD35 E. coli n/a IP 2 mg 72 h
27 Rat NR M DIO HFD60 E. coli n/a IP 2 mg 72 h
Suto, 2007 28 Mouse NR F Gen B6AY12w E. coli 0111-B4 n/a IP 50 μg 7 d
29 Mouse NR F Gen B6Ay12w E. coli 0111-B4 n/a IP 100 μg 7 d
30 Mouse NR F Gen B6-ob/ob E. coli 0111-B4 n/a IP 100 μg 7 d
31 Mouse NR F Gen B6Ay12w E. coli 0111-B4 n/a IP 200 μg 7 d
32 Mouse NR F Gen B6Ay10m E. coli 0111-B4 n/a IP 50 μg 7 d
33 Mouse NR F Gen B6Ay10m E. coli 0111-B4 n/a IP 100 μg 7 d
Sakai, 2013 34 Rat 4 M DIO HFD E. coli 0111-B4 n/a IP 10 mg/kg 24 h
Fujiwara, 2014 35 Rat 4 M DIO HFD E. coli 0111-B4 n/a IP 10 mg/kg 12 h
36 Rat 4 M DIO HFD E. coli 0111-B4 n/a IP 10 mg/kg 12 h
Single-strain virus models
Smith, 2007 37 Mouse NR NR DIO HFD H1N1 influenza A A/PR8 IN 2 HG units 10 d
Easterbrook, 2011 38 Mouse 20 M DIO HFD H1N1 influenza A CA/09 IN 2.5 × 105 pfu 15 d
39 Mouse 20 M DIO HFD H1N1 influenza A NY312 IN 2.5 × 105 pfu 15 d
40 Mouse 20 M DIO HFD H1N1 influenza A Sw31 IN 50ul-SW31 15 d
Milner, 2013 41 Mouse NR M DIO HFD-UP H1N1 influenza A A/PR8 PO 5.3 × 105 TCID50 13 d
42 Mouse NR M DIO HFD-P H1N1 influenza A A/PR8 PO 5.3 × 105TCID50 13 d
Radigan, 2014 43 Mouse 8–12 NR Gen db/db H1N1 influenza A A/WSN/33 IT 500 pu 14 d
44 Mouse 8–12 NR Gen db/db H1N1 influenza A A/WSN/33 IT 1500 pu 14 d
O'Brien, 2015∗ 45 Mouse 11 M DIO HFD H1N1 influenza A CA/09∗ IN 1 × 105 TCID50 10 d
46 Mouse 8 M Gen ob/ob H1N1 influenza A CA/09 IN 1 × 105 TCID50 10 d
47 Mouse 11 M DIO HFD H3N2 influenza A HK68 IN 6.3 × 105 TCID50 10 d
48 Mouse 8 M Gen ob/ob H3N2 influenza A HK68 IN 6.3 × 105 TCID50 10 d
Milner, 2015 49 Mouse 14–16 M DIO HFD H1N1 influenza A CA/09 IN 5.8 × 105 14 d
50 Mouse 14–16 M DIO HFD H1N1 influenza A CA/09 IN 1.3 × 103 14 d
51 Mouse 13–16 M Gen LepRH-/- H1N1 influenza A CA/09 IN 5.8 × 105 14 d
52 Mouse 13–16 F Gen LepRH-/- H1N1 influenza A CA/09 IN 5.8 × 105 14 d

B6-ob/ob: leptin-deficient mice; B6Ay10m and 12m: 10- and 12-week-old agouti peptide positive hyperphagic mice; CPE: lack functional carboxypeptidase enzyme; db/db: leptin receptor-deficient mice; DC: diet composition; DIO: diet-induced obesity; Exp: experiment; F: female; Gen: genetic-induced obesity; GT: genotype; HFD35: 35% of the energy from fat; HFD60: 60% of the energy from fat; HFD: high-fat diet; HFD-P: primed with virus; HFD-UP: unprimed; HFDP: polyunsaturated; HFDS-HP: high protein-to-carbohydrate ratio; HFDS-LP: low protein-to-carbohydrate ratio; HFDS: saturated; HFDw6: omega-6 fatty acid rich; IN: intranasal; IP: intraperitoneal; IT: intubation; IV: intravenous; LepRH-/-: lack leptin receptor signaling in hypothalamic neurons; M: male; n/a: not applicable; ob/ob: leptin-deficient mice; PO: oral administration; wk: week. ∗Oseltamivir treatment administered to animals.